Internal Medicine, Nephrology · North Kansas City, MO
NPI
1144485129
Since 2008
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2700 Clay Edwards Dr Ste 240
North Kansas City, MO, 64116
Phone (816) 455-0681
Groups this clinician bills Medicare through
Medicare paid, 2024
$213K
2,694 services
Medicare patients, 2024
600
Average age 74
Drug cost, 2024
$103K
1,558 prescriptions
Company payments, 2025
$783
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Najindra Maharjan was code 99232 (hospital e&m - subsequent), 748 times for 226 patients. In total Najindra Maharjan billed 2,694 services in 20 codes, and Medicare paid $213K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 748 | 226 | $59.75 | $45K |
| 99214 Office E&M - Established | Office | 392 | 265 | $67.26 | $26K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 301 | 217 | $12.33 | $3,710 |
| 90960 ESRD Related Services (not dialysis) | Office | 257 | 47 | $265.93 | $68K |
| 90970 ESRD Related Services (not dialysis) | Office | 226 | 20 | $7.01 | $1,584 |
| 99222 Hospital E&M - Initial | Facility | 155 | 144 | $99.44 | $15K |
| 90966 ESRD Related Services (not dialysis) | Office | 105 | 15 | $215.83 | $23K |
| 90935 Hemodialysis | Facility | 68 | 45 | $53.83 | $3,660 |
| 99204 Office E&M - New | Office | 48 | 48 | $113.46 | $5,446 |
| 90961 ESRD Related Services (not dialysis) | Office | 27 | 18 | $218.60 | $5,902 |
| 99231 Hospital E&M - Subsequent | Facility | 19 | 11 | $37.47 | $712 |
| 99223 Hospital E&M - Initial | Facility | 13 | 12 | $131.88 | $1,714 |
By year: 2022 $99K for 1,366 services; 2023 $182K for 2,295 services; 2024 $213K for 2,694 services.
Medicare prescription drug claims, 2024
In 2024, the drug Najindra Maharjan prescribed most often to Medicare patients was Amlodipine Besylate, with 125 prescriptions and refills. In total Najindra Maharjan wrote 1,558 Medicare prescriptions that cost $103K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 125 | 258 | 36 | $653 |
| Calcitriol Generic | 123 | 307 | 33 | $1,889 |
| Losartan Potassium Generic | 116 | 242 | 34 | $764 |
| Furosemide Generic | 94 | 200 | 31 | $443 |
| Lisinopril Generic | 78 | 164 | 24 | $591 |
| Carvedilol Generic | 77 | 172 | 23 | $556 |
| Allopurinol Generic | 74 | 218 | 23 | $808 |
| Hydralazine Hcl Generic | 68 | 132 | 14 | $422 |
| Potassium Chloride Generic | 52 | 96 | 14 | $570 |
| Torsemide Generic | 40 | 92 | 13 | $483 |
| Midodrine Hcl Generic | 38 | 56 | 12 | $1,921 |
| Hydrochlorothiazide Generic | 37 | 77 | Under 11 | $146 |
| Kerendia Finerenone | 33 | 37 | Under 11 | $24K |
| Demeclocycline Hcl Generic | 30 | 48 | Under 11 | $15K |
| Doxazosin Mesylate Generic | 30 | 48 | Under 11 | $294 |
Brand drugs: 118 claims; generic drugs: 1,440 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Najindra Maharjan $783 ($783 in general payments such as food, travel and fees) from 11 companies. The largest payer was Travere Therapeutics, Inc. with $213.
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. TVTX | 19 | $213 |
| Calliditas Therapeutics US Inc. | 7 | $149 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 4 | $90.74 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $55.68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $53.03 |
| GlaxoSmithKline, LLC. GSK | 2 | $52.53 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $50.39 |
| Novo Nordisk Inc NVO | 2 | $42.93 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $34.35 |
| Vifor Pharma, Inc. | 1 | $23.38 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.